AlzeCure Pharma
Research AlzeCure Pharma (ALZCUR) on Bullrun: market cap SEK 861.86M, P/E 22.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALZCUR
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 861.86M
- P/E22.7
- Financial periodQ1 2026
- RevenueSEK 0
- Net income-SEK 21.70M
- Free cash flow-SEK 17.09M
Valuation Snapshot
latest market cap is SEK 861.86M; P/E is 22.7.
Peer valuation comparison
Latest P/E is 22.73x versus a Healthcare sector median of 24.61x (7.6% below).
Latest P/E is 22.73x versus a Sweden median of 18.18x (25.0% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 47.61M | -SEK 35.12M | n/a | -0.45 | SEK 50.34M | SEK 2.56M | SEK 32.92M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-26 | SEK 861.86M | 22.7 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About AlzeCure Pharma
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is AlzeCure Pharma's market cap?
AlzeCure Pharma's market capitalization is SEK 861.86M.
What is AlzeCure Pharma's P/E ratio?
AlzeCure Pharma's price-to-earnings (P/E) ratio is 22.7.
What does AlzeCure Pharma do?
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms.